A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)

Key facts

Sponsor

BioMarin Pharmaceutical

Principal Investigator

Medical Director, MD

BioMarin Pharmaceutical

Enrollment

172 target

Eligibility

18 years · MALE

Timeline

2023 – 2040

Study locations (30)

• Orthopedic Institute for Children, Orthopedic Hemophilia Treatment Center, Los Angeles, California, United States
• UC Davis Hemophilia Treatment Center, Sacramento, California, United States
• University of California San Diego, Hemophilia & Thrombosis Treatment Center, San Diego, California, United States
• University of California San Francisco - Moffit Hospital, Outpatient Hematology Clinic, San Francisco, California, United States
• UCN Hemophilia and Thrombosis Center, Shandon, California, United States
• Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
• St Joseph's Children's Hospital, Center for Bleeding and Clotting Disorders, Tampa, Florida, United States
• University Medical Center, Inc,; DBA University of Louisville Hospital, James Graham Brown Cancer Center, Louisville, Kentucky, United States
• University of Michigan, Pediatric Hematology and Oncology, Ann Arbor, Michigan, United States
• Children's Hospital of Michigan, Hemophilia and Thrombosis Center, Detroit, Michigan, United States
• Washington University School of Medicine, Department of Pediatrics, Division of Hematology/Oncology, St Louis, Missouri, United States
• Nationwide Children's Hospital, Columbus, Ohio, United States
• Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
• Royal Prince Alfred Hospital, Institute of Haematology, Sydney, New South Wales, Australia
• Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Severe hemophilia A

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06816953
  Cartilage Biomarkers and HEAD-US Score in Severe Hemophilia A Patients Receiving FVIII Prophylaxis
  Chulalongkorn University
• RECRUITINGPHASE3NCT06142552
  Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
  Jiangsu Gensciences lnc.
• ACTIVE NOT RECRUITINGPHASE3NCT06224907
  Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A
  BioMarin Pharmaceutical
• RECRUITINGNCT05981274
  A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)
  Tri-Service General Hospital
• RECRUITINGPHASE4NCT04690322
  POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
  University of Texas Southwestern Medical Center

See all trials for Severe hemophilia A →